Empery Asset Management LP Buys Shares of 2,674,950 Immuneering Corporation $IMRX

Empery Asset Management LP bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,674,950 shares of the company’s stock, valued at approximately $17,601,000. Immuneering makes up about 15.6% of Empery Asset Management LP’s portfolio, making the stock its 2nd biggest position. Empery Asset Management LP owned approximately 4.14% of Immuneering at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Immuneering in the 1st quarter worth $32,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Immuneering in the 3rd quarter worth $35,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Immuneering in the 3rd quarter worth $70,000. Moors & Cabot Inc. acquired a new stake in shares of Immuneering in the 3rd quarter worth $77,000. Finally, XTX Topco Ltd acquired a new stake in shares of Immuneering in the 2nd quarter worth $90,000. Institutional investors own 67.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IMRX. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Immuneering in a research report on Tuesday, May 19th. Finally, Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Stock Performance

NASDAQ IMRX opened at $3.92 on Thursday. The stock has a 50-day simple moving average of $5.21 and a two-hundred day simple moving average of $5.46. The firm has a market capitalization of $253.62 million, a P/E ratio of -3.35 and a beta of 0.38. Immuneering Corporation has a fifty-two week low of $1.66 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. As a group, analysts forecast that Immuneering Corporation will post -1.12 earnings per share for the current year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.